MX2022014553A - Composicion farmaceutica para tratar enfermedad de higado graso. - Google Patents
Composicion farmaceutica para tratar enfermedad de higado graso.Info
- Publication number
- MX2022014553A MX2022014553A MX2022014553A MX2022014553A MX2022014553A MX 2022014553 A MX2022014553 A MX 2022014553A MX 2022014553 A MX2022014553 A MX 2022014553A MX 2022014553 A MX2022014553 A MX 2022014553A MX 2022014553 A MX2022014553 A MX 2022014553A
- Authority
- MX
- Mexico
- Prior art keywords
- sup
- sub
- fatty liver
- liver diseases
- formula
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/26—Oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
- C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020089196 | 2020-05-21 | ||
| JP2020134338 | 2020-08-07 | ||
| PCT/JP2021/019088 WO2021235508A1 (ja) | 2020-05-21 | 2021-05-20 | 脂肪性肝疾患の治療用医薬 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022014553A true MX2022014553A (es) | 2022-12-15 |
Family
ID=78707930
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022014553A MX2022014553A (es) | 2020-05-21 | 2021-05-20 | Composicion farmaceutica para tratar enfermedad de higado graso. |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US12521375B2 (https=) |
| EP (1) | EP4154880A4 (https=) |
| JP (1) | JP7820294B2 (https=) |
| KR (1) | KR20230013126A (https=) |
| CN (1) | CN115666558A (https=) |
| AU (1) | AU2021275292A1 (https=) |
| CA (1) | CA3182134A1 (https=) |
| MX (1) | MX2022014553A (https=) |
| TW (1) | TW202207919A (https=) |
| WO (1) | WO2021235508A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4434520A4 (en) | 2021-11-19 | 2025-10-29 | Shionogi & Co | PHARMACEUTICAL PRODUCT FOR THE TREATMENT OF HEART DISEASE OR SKELETAL MUSCLE DISEASE |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004523225A (ja) | 2000-12-26 | 2004-08-05 | リサーチ ディベロップメント ファンデーション | 脂肪燃焼、脂肪蓄積、エネルギーホメオスタシス及びインシュリン作用の調節を標的とするアセチルコエンザイムａカルボキシラーゼ２ |
| US6548738B2 (en) | 2000-12-26 | 2003-04-15 | Research Development Foundation | ACC2-knockout mice and uses thereof |
| US20110009443A1 (en) * | 2008-05-28 | 2011-01-13 | Kevin Daniel Freeman-Cook | Pyrazolospiroketone Acetyl-Coa Carboxylase Inhibitors |
| WO2011058474A1 (en) | 2009-11-10 | 2011-05-19 | Pfizer Inc. | N1-pyrazolospiroketone acetyl-coa carboxylase inhibitors |
| BR112013010310A2 (pt) | 2010-10-29 | 2016-11-29 | Pfizer | inibidores de acetil-coa carboxilase de lactama n1/n2 |
| LT2776038T (lt) | 2011-11-11 | 2018-04-25 | Gilead Apollo, Llc | Acc inhibitoriai ir jų panaudojimas |
| US20140187633A1 (en) | 2012-12-31 | 2014-07-03 | Amarin Pharmaceuticals Ireland Limited | Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis |
| JP6205152B2 (ja) | 2013-03-25 | 2017-09-27 | サイプレス セミコンダクター コーポレーション | シリアル通信システム、受信装置およびシリアル通信方法 |
| EP3670496A3 (en) | 2013-10-17 | 2020-09-30 | Shionogi&Co., Ltd. | Acc2 inhibitors |
| JP2016079168A (ja) | 2014-10-17 | 2016-05-16 | 塩野義製薬株式会社 | ９員縮合環誘導体 |
| JP2018501276A (ja) | 2015-01-09 | 2018-01-18 | ギリアド アポロ， エルエルシー | 非アルコール性脂肪肝疾患の処置のためのａｃｃ阻害剤併用療法 |
| EA201892201A1 (ru) * | 2016-03-30 | 2019-03-29 | Женфит | Неинвазивная диагностика неалкогольного стеатогепатита |
| US11541046B2 (en) | 2017-06-30 | 2023-01-03 | Quixgen, Inc. | Spirolactone compounds |
-
2021
- 2021-05-20 US US17/926,273 patent/US12521375B2/en active Active
- 2021-05-20 AU AU2021275292A patent/AU2021275292A1/en not_active Abandoned
- 2021-05-20 CA CA3182134A patent/CA3182134A1/en active Pending
- 2021-05-20 KR KR1020227044828A patent/KR20230013126A/ko not_active Withdrawn
- 2021-05-20 WO PCT/JP2021/019088 patent/WO2021235508A1/ja not_active Ceased
- 2021-05-20 JP JP2022524526A patent/JP7820294B2/ja active Active
- 2021-05-20 MX MX2022014553A patent/MX2022014553A/es unknown
- 2021-05-20 EP EP21808650.2A patent/EP4154880A4/en active Pending
- 2021-05-20 CN CN202180035760.4A patent/CN115666558A/zh active Pending
- 2021-05-21 TW TW110118449A patent/TW202207919A/zh unknown
-
2025
- 2025-12-09 US US19/413,251 patent/US20260091022A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20260091022A1 (en) | 2026-04-02 |
| JPWO2021235508A1 (https=) | 2021-11-25 |
| JP7820294B2 (ja) | 2026-02-25 |
| KR20230013126A (ko) | 2023-01-26 |
| CA3182134A1 (en) | 2021-11-25 |
| US12521375B2 (en) | 2026-01-13 |
| CN115666558A (zh) | 2023-01-31 |
| TW202207919A (zh) | 2022-03-01 |
| AU2021275292A1 (en) | 2022-12-15 |
| EP4154880A1 (en) | 2023-03-29 |
| EP4154880A4 (en) | 2024-06-05 |
| WO2021235508A1 (ja) | 2021-11-25 |
| US20230210822A1 (en) | 2023-07-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2004074270A3 (en) | Inhibitors of hepatitis c virus rna-dependent rna polymerase, and compositions and treatments using the same | |
| MA34013B1 (fr) | Inhibiteurs du virus de l'hépatite c | |
| MX2009006756A (es) | Derivados de 1-amino-metil-l-fenil-ciclohexano como inhibidores de dpp-iv. | |
| MA32135B1 (fr) | Inhibiteurs de pim kinase et leurs procedes d'utilisation | |
| DOP2004001052A (es) | Inhibidores heterociclil amino de 11-beta-hidroxiesteroide deshidrogenasa tipo 1 | |
| MX2026001061A (es) | Inhibidores de la fosfatidilinositol 3-cinasa (pi3k) | |
| WO2007127635A3 (en) | Diketo-piperazine and piperidine derivatives as antiviral agents | |
| AR058780A1 (es) | Imidazopirazinas como inhibidores de quinasas dependientes de ciclina | |
| EA200802288A1 (ru) | Замещенные имидазолы, композиция на их основе, способ профилактики или лечения нежелательного тромбообразования с их помощью и способ ингибирования коагуляции образцов крови | |
| EA200401519A1 (ru) | N- ациламинобензольные производные в качестве селективных ингибиторов моноаминооксидазы b | |
| MA31761B1 (fr) | Nouveaux inhibiteurs de seh et leur utilisation | |
| NO20070605L (no) | Nye 2-substituerte D-homoostra-1,3,5(10)-triener som inhibitor av 17(3-hydroksysteroiddehydrogenaser type-1. | |
| DK1753723T3 (da) | Substituerede quinolinderivater som mitotiske kinesininhibitorer | |
| UA87822C2 (ru) | Производные нафтилена как ингибиторы цитохрома p450 | |
| MX2022014553A (es) | Composicion farmaceutica para tratar enfermedad de higado graso. | |
| CO5080752A1 (es) | INHIBIDORES DEL FACTOR DE TRANSCRIPCION NF-kB | |
| MX2007006744A (es) | Derivados de hidantoina utiles como inhibidores de metaloproteinasa. | |
| JOP20240183A1 (ar) | مثبطات بروتين رابط لإموباميل واستخداماتها | |
| EP4248960A3 (en) | Novel triterpene derivatives as hiv inhibitors | |
| AR050043A1 (es) | Metodos para mejorar la biodisponibilidad y composicion farmaceutica para trastornos cardiovasculares | |
| WO2006129168A3 (en) | Bicyclic derivatives for the treatment of abnormal cell growth | |
| RU2008129623A (ru) | Ингибиторы ccr9 активности | |
| ATE432262T1 (de) | Pyrazolphenylderivate als ppar-aktivatoren | |
| MX2022007488A (es) | Agentes terapeuticos selectivos contra el cancer inhibidores de cdk4/6. | |
| WO2006013049A3 (en) | Benzyloxy derivatives as maob inhibitors |